Associate Professor, Department of Pathology, Harvard Medical School; Director, Noncoding RNA Core, Beth Israel Deaconess Medical Center
Win Hide applies systems biology approaches to genomic data to reveal and drug critical disease processes occurring in neurodegeneration. This makes it possible to build and implement systems that allow the discovery and prioritization of key target genes and processes involved in complex diseases like Alzheimer’s. He has been funded by key industry partners, including Biogen Inc., to develop translational pipelines for target prioritization. His bibliography details his research.
His work with CureAlz explores the controlling molecules (miRNAs) and genome variation in Alzheimer’s subjects to try and discover early biomarkers that can be detected in the blood, and upstream regulators of the initiation of Aleheimer’s. Using these, Hide is now developing ways in which we can enhance the body’s natural resilience against neurodegeneration – protecting before we need to treat.
Win received a bachelor’s degree in zoology from the University of Wales, Cardiff, and a doctorate degree in molecular genetics from Temple University, Philadelphia. He performed postdoctoral training at the University of Texas, Houston, at the Baylor College of Medicine and at the Smithsonian Institution Museum of Natural History. He gained industry experience in Silicon Valley at the MasPar Computer Corporation while serving as director of genomics.
